Drug Profile
Research programme: autoimmune and inflammatory therapeutics - VLST/Novo Nordisk
Latest Information Update: 25 Jun 2014
Price :
$50
*
At a glance
- Originator Novo Nordisk; VLST Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 25 Jun 2014 Discontinued for Autoimmune disorders in USA (unspecified route)
- 25 Jun 2014 Discontinued for Inflammation in USA (unspecified route)
- 18 Dec 2008 Early research in Autoimmune disorders in USA (unspecified route)